Mucolipidosis IV Foundation
ML4 is a genetic disease causing mental retardation, retinal degeneration, and limited lifespan. The mission of the Foundation is to fund, promote, and support medical research dedicated to developing treatments and a cure for ML4.
Medical Advisory Board
Roscoe O. Brady, M.D.
National Institutes of Health
Jordan B. Glaser, M.D.
Staten Island Univ. Hospital
Staten Island, New York
James F. Gusella, Ph.D.
Harvard Medical Center
Massachusetts General Hospital
Irene H. Maumenee, M.D.
Johns Hopkins University
Baltimore, Maryland
Craig Montell, Ph.D.
The Johns Hopkins School of Medicine
Isabelle Rapin, M.D.
Albert Einstein College of Medicine
Bronx, New York
Gary P. Schwartz, M.D.
Chief of Cardiology, USAF, Retired
Chief Medical Officer, DEA, Retired
Susan A. Slaugenhaupt, Ph.D.
Harvard Medical Center
Massachusetts General Hospital
Steven U. Walkley, D.V.M., Ph,D.
Albert Einstein Medical Center
Bronx, NY
Randy Gold, ML4 Foundation Vice President, was named the 2011 Jewish Community Hero sponsored by the Jewish Federations® of North America for his efforts around promoting awareness of the 19 known preventable Jewish Genetic Diseases.
